Immunity to liver-stage Plasmodium falciparum malaria parasites

Not Applicable

Conditions: Antimalarial immune response to liver-stage P. falciparum
Infections and Infestations

Registration Number: ISRCTN61332343

Lead Sponsor: Radboud University Nijmegen Medical Centre

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Ongoing

Sex: All

Target Recruitment: 45

Inclusion Criteria

1. Aged 18 years and above
2. Scheduled for partial liver resection for underlying disease
3. Signed written informed consent

Exclusion Criteria

1. Known receipt of immunosuppressive or cytostatic agents within the past 3 months, except the use of topical and inhaled steroids
2. Known human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) infection, or other known clinically-relevant immunodeficient state

Study & Design

Study Type: Observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Measured at the surgery visit:<br>1. Recognition of P. falciparum-infected hepatocytes by CSP-specific cytolytic CD8+ T cells and hepatic and peripheral innate/innate-like lymphocytes measured using flow cytometry<br>2. Killing of P. falciparum-infected hepatocytes by CSP-specific cytolytic CD8+ T cells and hepatic and peripheral innate/innate-like lymphocytes measured using fluorescence microscopy

Secondary Outcome Measures

Name	Time	Method
Measured at the surgery visit:<br>1. Recognition and killing of P. falciparum-infected hepatocytes by CSP-specific cytolytic CD8+ T cell line measured using flow cytometry and fluorescence microscopy<br>2. Differences in recognition and killing of P. falciparum-infected hepatocytes between liver-resident and peripheral lymphocytes measured using flow cytometry and fluorescence microscopy<br>3. The individual lymphocyte (sub-)populations which contribute to the recognition and killing of P. falciparum-infected hepatocytes, identified using flow cytometry